DF-6000 is under clinical development by Dragonfly Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DF-6000’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DF-6000 was under development for the treatment of unspecified cancer. The drug candidate is a tri-specific monoclonal antibody that acts by targeting NKG2D receptor, CD16 and tumor specific antigen. It is being developed based on tri-specific NK cell engagement therapies (TriNKET) technology platform.
It is under development for the treatment of solid tumor.
Dragonfly Therapeutics overview
Dragonfly Therapeutics (Dragonfly) is a bio-technology company that discovers, develops and commercializes novel immunotherapies to treat cancer. It is investigating tri-specific, NK (natural killer) cell engager therapies against solid and hematological cancers. The company utilizes its proprietary NK cell based TriNKET platform technology to develop anticancer drugs. It works in partnership with University of Washington, The University of Chicago, Seattle Children’s hospital, Massachusetts Institute of Technology and other companies. Dragonfly is headquartered in Waltham, Massachusetts, the US.
For a complete picture of DF-6000’s drug-specific PTSR and LoA scores, buy the report here.